Effects of Pediatric Liver Adiposity on Statin Disposition and Response
Children's Mercy Hospital Kansas City
Summary
Single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT genotype that are dosed rosuvastatin
Eligibility
- Age range
- 8–21 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * 8-21 years * LDL cholesterol \>130mg/dl (\>95% percentile) * SLCO1B1 c.521TT genotype * Provide informed permission-assent(\<18 yrs.) or consent (≥18 yrs.) * Fasting overnight (\~8 hrs.) * Enrolled in Cardiology Pharmacogenomic Repository Exclusion Criteria: * Pregnancy * Non-fasting * Non-removable metal in body or MRI unsafe * Currently on statin therapy and unwilling to wash out of statin therapy for at least 4 weeks prior to Visit 1 and throughout the duration of the study. * Underlying unrepaired congenital or acquired cardiovascular defects or repaired congenital…
Interventions
- DrugRosuvastatin 10mg
Rosuvastatin will be administered to all participants on Study Day #2
Location
- Children's Mercy HospitalKansas City, Missouri